布格替尼用于克唑替尼难治性ALK阳性非小细胞肺癌:一项随机多中心II期试验
这项随机多中心II期试验纳入222例克唑替尼难治性ALK阳性非小细胞肺癌患者,按1:1随机接受布格替尼90 mg每日一次(A组)或180 mg每日一次(先以90 mg导入7天,B组)。研究者评估的确认客观缓解率A组为45%,B组为54%;中位无进展生存期分别为9.2个月和12.9个月。B组疗效一致优于A组,安全性可接受。
要点
- 布格替尼180 mg(先90 mg导入7天)较90 mg在克唑替尼难治性ALK阳性非小细胞肺癌中显示一致更好的疗效。
- 研究者评估的确认客观缓解率A组45%、B组54%,中位无进展生存期分别为9.2个月和12.9个月。
- 基线可测量脑转移患者中,独立评审委员会评估的颅内客观缓解率A组42%(26例中11例)、B组67%(18例中12例)。
核心结论
- 布格替尼产生了显著的全身和颅内缓解以及稳健的无进展生存期;180 mg(先90 mg导入7天)较90 mg显示一致更好的疗效,且安全性可接受。
研究设计与样本
- 随机、多中心II期试验,纳入克唑替尼难治性ALK阳性非小细胞肺癌患者222例,按脑转移和克唑替尼最佳疗效分层后1:1随机分组。
- A组接受布格替尼90 mg每日一次口服(n=112,109例接受治疗),B组接受180 mg每日一次口服、先以90 mg导入7天(n=110,110例接受治疗)。
- 主要终点为研究者评估的确认客观缓解率。
主要发现
- 中位随访8.0个月,研究者评估的确认客观缓解率A组为45%(97.5% CI,34%至56%),B组为54%(97.5% CI,43%至65%)。
- 研究者评估的中位无进展生存期A组为9.2个月(95% CI,7.4至15.6),B组为12.9个月(95% CI,11.1至未达到)。
- 基线有可测量脑转移的患者中,独立评审委员会评估的颅内客观缓解率A组为42%(26例中11例),B组为67%(18例中12例)。
- 常见治疗中出现的不良事件为恶心(A组/B组,33%/40%)、腹泻(A组/B组,19%/38%)、头痛(A组/B组,28%/27%)和咳嗽(A组/B组,18%/34%),主要为1至2级。
- 219例接受治疗患者中14例发生早发性肺部不良事件(中位发生时间:第2天;所有级别6%,≥3级3%),B组剂量递增至180 mg后未再发生;14例中7例成功再次接受布格替尼治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene ( ALK)-rearranged non-small-cell lung cancer (ALK-positive NSCLC) eventually experience disease progression. We evaluated two regimens of brigatinib, an investigational next-generation ALK inhibitor, in crizotinib-refractory ALK-positive NSCLC. Patients and Methods Patients were stratified by brain metastases and best response to crizotinib. They were randomly assigned (1:1) to oral brigatinib 90 mg once daily (arm A) or 180 mg once daily with a 7-day lead-in at 90 mg (180 mg once daily [with lead-in]; arm B). Investigator-assessed confirmed objective response rate (ORR) was the primary end point. Results Of 222 patients enrolled (arm A: n = 112, 109 treated; arm B: n = 110, 110 treated), 154 (69%) had baseline brain metastases and 164 of 222 (74%) had received prior chemotherapy. With 8.0-month median follow-up, investigator-assessed confirmed ORR was 45% (97.5% CI, 34% to 56%) in arm A and 54% (97.5% CI, 43% to 65%) in arm B. Investigator-assessed median progression-free survival was 9.2 months (95% CI, 7.4 to 15.6) and 12.9 months (95% CI, 11.1 to not reached) in arms A and B, respectively. Independent review committee-assessed intracranial ORR in patients with measurable brain metastases at baseline was 42% (11 of 26 patients) in arm A and 67% (12 of 18 patients) in arm B. Common treatment-emergent adverse events were nausea (arm A/B, 33%/40%), diarrhea (arm A/B, 19%/38%), headache (arm A/B, 28%/27%), and cough (arm A/B, 18%/34%), and were mainly grades 1 to 2. A subset of pulmonary adverse events with early onset (median onset: day 2) occurred in 14 of 219 treated patients (all grades, 6%; grade ≥ 3, 3%); none occurred after escalation to 180 mg in arm B. Seven of 14 patients were successfully retreated with brigatinib. Conclusion Brigatinib yielded substantial whole-body and intracranial responses as well as robust progression-free survival; 180 mg (with lead-in) showed consistently better efficacy than 90 mg, with acceptable safety.
引用
- Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017. PMID: 28475456. doi:10.1200/JCO.2016.71.5904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。